
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
See how well-versed you are in acute coronary syndrome knowledge.
See how well-versed you are in acute coronary syndrome knowledge.






